Therefore, dual inhibitors targeting host CTSL and CAPN1 might bring broad-spectrum synergistic efficacy to the fight against coronavirus in the future, while reducing excess inflammation to improve symptoms in patients with viral infections. This evidence concerns the gene CTSL and viral infectious disease.